Novo Nordisk Launches Diabetes Program in India - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novo Nordisk Launches Diabetes Program in India


ePT--the Electronic Newsletter of Pharmaceutical Technology

Novo Nordisk announced the roll-out of its Changing Diabetes in Children program in India, making India the seventh country to participate. The aim of the program is to contribute to meeting the fourth UN Millennium Goal—to reduce child mortality—by breaking down the barriers that prevent children with Type I diabetes in developing countries from receiving proper care. The program is currently operating in six countries—Bangladesh, Cameroon, the Democratic Republic of the Congo (DRC), Guinea, Tanzania, and Uganda, and Novo Nordisk plans to launch the program in Kenya within the next few months.

The program provides free insulin, blood glucometers and strips for children with Type I diabetes. A comprehensive training manual for healthcare professionals and diabetes educators has been developed as well as locally adapted educational materials for children and their families. In India, there are plans to open 12 Changing Diabetes in Children clinics covering a total of 10 Indian stages, making it the most extensive program launch to date.

It is estimated that there are 50 million people living with diabetes in India, and the program’s goal is to reach 2500 children by its completion in 2015. By that time, a sustainable cooperation with local partners, including governments and diabetes foundations should be in place. The program is designed to provide immediate, short-term access to diabetes care, while building a framework for a lasting and long-term solution. According to the program’s website, “When the Changing Diabetes in Children program ends, our hope and intention is that it is properly embedded in the national healthcare systems and will continue as a government initiative.”

 

See Related Pharm Tech Stories:

Global Healthcare on the Ground: IFPMA Engages Global Bodies to Push Health Efforts Forward

Global Healthcare on the Ground: NIH Aims to Help Treat 200 Rare Diseases

Global Healthcare on the Ground: BIO and BIO Ventures for Global Health

Global Healthcare on the Ground: GlaxoSmithKline's Efforts

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here